EGFR and non-small cell lung carcinoma: These two EGFR-TKIs are clinically usedfor NSCLC patients whose tumors are driven by mutations in EGFR. 31 In particular, osimertinibis applied when EGFR harbors the compensatory EGFR mutation T790Min exon 20.